| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P2093 | author name string | Sanjaykumar Hapani | |
| Shenhong Wu | |||
| Vishal Ranpura | |||
| Jeff Chuang | |||
| P2860 | cites work | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| Meta-analysis in clinical trials | Q27860779 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Arterial thrombosis in four patients treated with thalidomide | Q28212339 | ||
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
| Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells | Q28249984 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Role of angiogenesis in tumor growth and metastasis | Q29614309 | ||
| Quantitative synthesis in systematic reviews | Q29614894 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice | Q33381903 | ||
| Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer | Q33384357 | ||
| Molecular mechanisms of tumor angiogenesis and tumor progression | Q34178900 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| Managing patients treated with bevacizumab combination therapy. | Q36319038 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 | ||
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 | Q37117085 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis | Q37501707 | ||
| Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries | Q41095909 | ||
| Selecting and appraising studies for a systematic review | Q41602557 | ||
| Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. | Q44486167 | ||
| Bevacizumab, bleeding, thrombosis, and warfarin | Q44583981 | ||
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer | Q45106840 | ||
| Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | Q46329140 | ||
| Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? | Q46397863 | ||
| Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer | Q46502913 | ||
| Arterial and venous thrombotic complications with thalidomide in multiple myeloma. | Q46828682 | ||
| Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer | Q46972019 | ||
| Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues | Q47341098 | ||
| Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. | Q51022937 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| P433 | issue | 3 | |
| P921 | main subject | patient | Q181600 |
| thromboembolism | Q891391 | ||
| bevacizumab | Q413299 | ||
| angiogenesis inhibitor | Q574834 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 287-297 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Acta Oncologica | Q326164 |
| P1476 | title | Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials | |
| P478 | volume | 49 |
| Q98945974 | A case of chemotherapy-induced coronary vasospasm in a patient with colorectal cancer |
| Q48318254 | A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network |
| Q45030405 | A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. |
| Q52628568 | A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. |
| Q37052843 | A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. |
| Q48747309 | Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration |
| Q28534015 | Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis |
| Q34554380 | Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future |
| Q54117069 | Arterial Thrombosis in Patients with Cancer. |
| Q34627103 | Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. |
| Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
| Q35202464 | Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). |
| Q26776307 | Bevacizumab for glioblastoma |
| Q37994752 | Bevacizumab in endometrial cancer treatment |
| Q40972698 | Bevacizumab safety in Japanese patients with colorectal cancer |
| Q36862836 | Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study |
| Q38010797 | Bevacizumab: overview of the literature |
| Q38538490 | Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare |
| Q33439089 | Cancer and Venous Thromboembolic Disease: A Review |
| Q39249961 | Cancer as a Risk Factor for Cardiovascular Disease |
| Q38805391 | Cancer associated thrombosis: risk factors and outcomes |
| Q49722419 | Cancer patients in operative intensive care medicine |
| Q35703835 | Cancer therapy and cardiovascular risk: focus on bevacizumab |
| Q38371293 | Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients |
| Q45073137 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. |
| Q38744149 | Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management |
| Q36751861 | Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives |
| Q38001305 | Cardiovascular medications in angiogenesis--how to avoid the sting in the tail |
| Q35584182 | Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies |
| Q53276936 | Cardiovascular toxic effects of targeted cancer therapy. |
| Q37960873 | Cardiovascular toxicity of anti-angiogenic drugs |
| Q37967508 | Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology |
| Q55176159 | Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. |
| Q38088974 | Chemotherapy-related cardiotoxicity |
| Q36473024 | Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab |
| Q42001807 | Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuita |
| Q53225923 | Current opinion on bevacizumab on endometrial cancer treatment. |
| Q21261282 | Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib |
| Q30616602 | Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q26786618 | Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q37390503 | Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential |
| Q54337584 | Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. |
| Q58777030 | Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer |
| Q38842771 | From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. |
| Q49997360 | Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors |
| Q34637564 | Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancer |
| Q33904867 | Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis |
| Q38704738 | Involvement of ion channels and transporters in carcinoma angiogenesis and metastasis. |
| Q51089877 | Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. |
| Q33441165 | Ischemic Heart Disease: Special Considerations in Cardio-Oncology |
| Q52597188 | Ischemic stroke in cancer patients: A review of an underappreciated pathology. |
| Q51375392 | Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. |
| Q29994512 | Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective |
| Q36170252 | Management of antiangiogenic therapy-induced hypertension |
| Q50209212 | Management of the toxicities of common targeted therapeutics for gynecologic cancers |
| Q35562745 | Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers |
| Q37038711 | Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond |
| Q38110320 | Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. |
| Q90461158 | MicroRNAs in Cancer Treatment-Induced Cardiotoxicity |
| Q45740557 | Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab |
| Q38153444 | Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer |
| Q50048895 | Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis |
| Q91691611 | Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity |
| Q36318627 | NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy |
| Q37696872 | Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy |
| Q36766221 | Neurotoxicity of biologically targeted agents in pediatric cancer trials |
| Q33564645 | New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management |
| Q27024715 | Noninvasive imaging of cardiovascular injury related to the treatment of cancer |
| Q51752830 | Outcome of acute limb ischemia in cancer patients. |
| Q38741548 | Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System |
| Q38155199 | Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity |
| Q94526353 | Pharmacological cancer treatment and venous thromboembolism risk |
| Q88016786 | Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema |
| Q89977542 | Potential Mechanisms of Cancer-Related Hypercoagulability |
| Q37801665 | Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration |
| Q33683537 | Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas. |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q42158334 | RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA. |
| Q36008274 | Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials |
| Q47837536 | Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis |
| Q37042424 | Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review |
| Q37161885 | Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis. |
| Q38693165 | SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa i |
| Q41947800 | Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer |
| Q37885753 | Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature |
| Q37954162 | Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients |
| Q38904546 | The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients |
| Q28550616 | The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells |
| Q37833645 | The role of bevacizumab in colorectal cancer: understanding its benefits and limitations |
| Q40975248 | Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials |
| Q37719815 | Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study |
| Q89083835 | Toxicity of Cancer Therapies in Older Patients |
| Q33400564 | Treating venous thromboembolism in patients with cancer |
| Q54386535 | Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. |
| Q37887823 | Trials of bevacizumab in breast cancer--a safety review |
| Q38813467 | Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System? |
| Q36894689 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. |
| Q40898144 | Use of Vacuum-assisted closure in management of open abdominal wound with multiple enterocutaneous fistulae during chemotherapy: A case report |
| Q36942426 | Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy |
| Q26766269 | Vascular Complications of Cancer Chemotherapy |
| Q36755620 | Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. |
| Q38156262 | Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors |
| Q52716139 | Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. |
| Q91911514 | [Cancer patients in operative intensive care medicine] |
Search more.